Status: Recruiting
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.
Participants needed: 2,500
Trial details
Age: 16-70Biological sex: AllType: InterventionalSponsor: Parnassia GroepUpdated: Jun 2, 2026Locations: 9
Eligibility criteria
Suffer from a depressive episode (major depressive disorder and bipolar disorder... [+7]
Patients with a history of prior pharmacogenomic testing [+10]